stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. SEER
    stockgist
    HomeTop MoversCompaniesConcepts
    SEER logo

    Seer, Inc.

    SEER
    NASDAQ
    Healthcare
    Biotechnology
    Redwood City, CA, US134 employeesseer.bio
    $1.71
    +0.01(0.29%)

    Mkt Cap $96M

    $1.66
    $2.37

    52-Week Range

    At a Glance

    AI-generated
    8-K
    PTAB upheld 23 claims of Seer Inc.'s U.S. Patent No. 11,435,360, including five challenged claims, validating the company's nanoparticle protein enrichment technology for the Proteograph platform.

    $96M

    Market Cap

    $16M

    Revenue

    -$72M

    Net Income

    Employees134
    Fundamentals

    How The Business Makes Money

    Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

    Industry Biotechnology
    Activity

    What Changed Recently

    Material Agreement
    Mar 15, 2026

    Entry into a Material Definitive Agreement. On March 13, 2026, Seer, Inc. (the “Company”) entered into Amendment No. 1 to Tax Benefit Preservation Plan (the “Am

    Financial Results
    Feb 25, 2026

    in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Secu

    Other Event
    Mar 29, 2026

    | Other Events. | |---|---| On March 30, 2026, Seer, Inc. announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issu

    Material Agreement+3 More
    Feb 25, 2026

    Entry into a Material Definitive Agreement. As of February 26, 2026, the Board of Directors (the “Board”) of Seer, Inc. (the “Company”) authorized and declared

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    KYMRKymera Therapeutics, Inc.$85.33+0.47%$7.0B-20.9
    PHVSPharvaris N.V.$28.50-3.21%$1.9B-8.3
    MLYSMineralys Therapeutics, I...$27.00+2.25%$1.8B-12.3
    NRIXNurix Therapeutics, Inc.$15.51+0.16%$1.3B-5.3
    GLUEMonte Rosa Therapeutics, ...$17.09-0.50%$1.1B-25.5
    ORICORIC Pharmaceuticals, Inc...$8.90+19.06%$893M-7.5
    CGEMCullinan Therapeutics, In...$14.45+3.66%$875M-3.5
    SANASana Biotechnology, Inc.$3.21+5.08%$855M-3.2
    Analyst View
    Company Profile
    CIK0001726445
    ISINUS81578P1066
    CUSIP81578P106
    Phone650 453 0000
    Address3800 Bridge Parkway, Redwood City, CA, 94065, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice